Answer to Question 1
2, 3, 4
Rationale 1: Sore throat is not a symptom of hypersensitivity.
Rationale 2: The client should discontinue the medication and inform the healthcare provider if symptoms of hypersensitivity reaction develop, such as wheezing; shortness of breath; swelling of face, tongue, or hands; and itching or rash.
Rationale 3: The client should discontinue the medication and inform the healthcare provider if symptoms of hypersensitivity reaction develop, such as wheezing; shortness of breath; swelling of face, tongue, or hands; and itching or rash.
Rationale 4: The client should discontinue the medication and inform the healthcare provider if symptoms of hypersensitivity reaction develop, such as wheezing; shortness of breath; swelling of face, tongue, or hands; and itching or rash.
Rationale 5: While diarrhea may occur with this medication, it is not a reason to stop the medication and inform the healthcare provider.
Global Rationale: The client should discontinue the medication and inform healthcare provider if symptoms of hypersensitivity reaction develop, such as wheezing; shortness of breath; swelling of face, tongue, or hands; and itching or rash. Sore throat is incorrect because it is not a symptom of hypersensitivity. While diarrhea may occur with this medication, it is not a reason to stop the medication and inform the healthcare provider.
Answer to Question 2
2, 3, 4
Rationale 1:Hepatotoxicity is incorrect because it is not caused by amphotericin B.
Rationale 2: Phlebitis, or inflammation of the veins, is common during IV therapy.
Rationale 3: Some degree of nephrotoxicity is observed in most patients, and laboratory tests of kidney function (creatinine and blood urea nitrogen BUN) are normally performed throughout the treatment period.
Rationale 4: Many patients develop fever and chills at the beginning of therapy, which subside as treatment continues. Some degree of nephrotoxicity is observed in most patients, and laboratory tests of kidney function are normally performed throughout the treatment period.
Rationale 5:Cardiac irregularities are not associated with amphotericin B therapy.
Global Rationale: Many patients develop fever and chills at the beginning of therapy, which subside as treatment continues. Some degree of nephrotoxicity is observed in most patients, and laboratory tests of kidney function such as creatinine and blood urea nitrogen (BUN)are normally performed throughout the treatment period. Phlebitis, or inflammation of the veins, is common during IV therapy.